

1 **Economic evaluation of *Wolbachia* deployment in Colombia: A modeling study**

2

3 Short title: Economic evaluation of *Wolbachia* in Colombia

4

5 Donald S. Shepard, PhD<sup>a</sup>

6 Samantha R. Lee, MS, MA<sup>a</sup>

7 Yara A. Halasa-Rappel, DMD, PhD<sup>a</sup>

8 Carlos Willian Rincon Perez, MS<sup>b</sup>

9 Arturo Harker Roa, PhD<sup>b</sup>

10

11 <sup>a</sup>Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, USA

12 <sup>b</sup>School of Government, University of Los Andes, Bogotá, Colombia

13

14 Correspondence: Donald S. Shepard, The Heller School for Social Policy and Management, Brandeis

15 University, Waltham, MA 02454-9110, USA. Email: [shepard@brandeis.edu](mailto:shepard@brandeis.edu)

16

17 **ABSTRACT**

18 Background and Aims

19 *Wolbachia* are bacteria that inhibit dengue virus replication within the mosquito. A cluster-randomized  
20 trial found *Wolbachia* reduced virologically-confirmed dengue cases by 77% and previous models  
21 predicted *Wolbachia* to be highly cost-effective in Indonesia, Vietnam, and Brazil. In Colombia,  
22 *Wolbachia* was introduced in the Aburrá Valley in 2015 and Cali in 2020. To inform decisions about  
23 future extensions, we performed economic evaluations of the potential expansion of *Wolbachia*  
24 deployments to 11 target Colombian cities.

25 Methods

26 We assembled quantities and the distribution by severity of reported dengue cases from Colombia's  
27 national disease surveillance system and the health service provision registry (RIPS). An epidemiological  
28 panel of three experts estimated the shares of non-medical cases and adjustments for under-reporting  
29 and misclassifications. We determined costs (in 2020 US dollars) of treating dengue illness from the  
30 benchmark insurance tariff, RIPS data on treatment services per symptomatic dengue case, and the  
31 national government database for establishing insurance premiums. A cluster randomized trial  
32 quantified the effectiveness of *Wolbachia* against symptomatic dengue cases.

33 Results

34 Projecting impact over 10 years for Cali, we estimated a net health-sector savings of USD4.95 per  
35 person. We also estimated averting 369 disability-adjusted life years (DALYs) per 100,000 population.  
36 From a societal perspective, at 10 years *Wolbachia* deployment is expected to have highly favorable  
37 benefit-cost ratios, with benefits per dollar invested of \$5.50 in Cali and USD4.68 over all target cities.

38 Conclusions

39 Over 10 years, *Wolbachia* is highly beneficial on economic grounds, and almost universally cost saving.  
40 That is, *Wolbachia*'s savings in health care costs alone would more than offset deployment costs  
41 nationally and in 9 target cities (those with adjusted annual dengue incidence at least 50/100,000  
42 population). In these 9 target cities, *Wolbachia* would generate at least USD3.00 in benefits per dollar  
43 invested, giving substantial confidence that *Wolbachia* deployment would be cost-beneficial in  
44 Colombia.

45

46 **Key words:**

47 Dengue, Colombia, *Wolbachia*, Cost-effectiveness analysis, Benefit-cost analysis, Mosquito control

49 **Introduction**

50 Dengue, responsible for dengue fever and dengue hemorrhagic fever, is the most widespread vector-  
51 borne virus in the southern hemisphere.[1] Colombia has experienced recent dengue epidemics in  
52 2010, 2013, and 2019.[2]

53 *Wolbachia* are common bacteria that naturally infect fruit flies and many other insects.  
54 Researchers at the World Mosquito Program (WMP) discovered that they could infect *Aedes aegypti*  
55 mosquitoes with these bacteria[3] and that dengue, chikungunya and Zika viruses are then less able  
56 to replicate within the insects, thereby inhibiting the transmission of these mosquito-borne  
57 infections.[4] To use this method for disease control, governments, communities, and international  
58 organizations (e.g., the WMP) partner to grow mosquitoes infected with *Wolbachia* in insectaries and  
59 then deploy eggs or adult mosquitoes to establish the bacteria in the local mosquito population.  
60 *Wolbachia*-infected mosquitoes transmit the bacteria through their eggs to the next generation. This  
61 approach is termed the “replacement” strategy, as it tends to replace wild mosquitoes by *Wolbachia*-  
62 infected ones. Thus, the establishment of *Wolbachia* becomes a sustainable and often long-term  
63 control mechanism at that site. The replacement approach was first applied near Cairns, Australia.  
64 Over a decade after initial deployment, mosquitoes there remain infected with the bacteria,  
65 supporting the long-term viability of the approach.[5] The replacement approach is being applied in  
66 countries in the Americas, Asia, and Oceania.[6]

67 Under a different approach, the *Wolbachia* suppression strategy, Singapore releases only male  
68 *Wolbachia* infected mosquitoes.[3] When these mosquitoes mate with wild mosquitoes, the eggs do  
69 not hatch, thereby reducing the number of potentially disease-carrying insects. While experience to  
70 date has found this approach efficacious, the need for annual releases makes the suppression

71 approach more costly but potentially economically viable in this high-income country.[7] The  
72 remainder of this paper considers only the replacement approach.

73 A landmark cluster-randomized trial in Yogyakarta, Indonesia found that the replacement  
74 strategy reduced all virologically-confirmed symptomatic dengue cases by 77.1% and hospitalized  
75 cases by 86.2% under the original protocol analysis.[8] A reanalysis that corrected for the attenuation  
76 due to border crossing by humans and mosquitoes raised the estimated efficacy against dengue cases  
77 to 82.7%.[9] A subsequent cluster randomized trial is underway in Belo Horizonte, Brazil. A quasi-  
78 experimental study from Niterói, Brazil found that *Wolbachia* reduced incidence of dengue by 69%, of  
79 chikungunya by 56%, and of Zika by 37%.[10] Research in Rio de Janeiro has shown that the  
80 technique is generally robust. Even in neighborhoods where *Wolbachia* coverage was low, such in  
81 *favelas* where access was difficult, dengue infections were still reduced by 38% and chikungunya by  
82 10%.[11]

83 In Colombia, pilot *Wolbachia* releases began in the city of Bello in 2015 and were expanded in  
84 2017 to city-wide deployments throughout Medellín, Itagui and Bello in the Aburrá Valley. An  
85 evaluation based on routine disease surveillance data reported reductions in notified dengue  
86 incidence of 95% to 97% in the three cities following *Wolbachia* introduction, compared to the prior  
87 decade; a parallel case-control study in Medellín also showed significantly lower dengue incidence in  
88 *Wolbachia*-treated neighborhoods compared to untreated ones.[12-15] Deployment progressed to  
89 Cali, with phased releases since 2020. In May 2023, Cali's coverage reached 50% and the  
90 departmental and municipal governments announced the expansion of *Wolbachia* to Yumbo  
91 municipality, 13 km northeast of Cali.[16]

92           *Wolbachia* is predicted to be a highly cost-effective intervention for controlling mosquito-  
93 borne illnesses, especially when released in high-density urban areas. In Indonesia, *Wolbachia* was  
94 projected to have a cost-effectiveness ratio in US dollars (USD) of USD1500 per disability-adjusted life  
95 year (DALY) averted, offsetting much of the costs to the health system and to society with benefit-  
96 cost ratios ranging from 1.35 to 3.40.[17] In Vietnam, another study found the technology similarly  
97 cost effective based on the 10-year time horizon, and cost-saving at the 20-year time horizon.[18] A  
98 simulation across seven Brazilian cities also found *Wolbachia* cost-effective across all 7 cities  
99 modeled, though not cost saving[19] in 2 of the 7 cities. In Suva, Fiji, a much smaller city, *Wolbachia*  
100 was acceptably cost-effective, but in Port Vila, Vanuatu, the relatively small target population and  
101 lower population density would not make the approach cost-effective there.[20] A simulation for  
102 Thailand suggested that *Wolbachia* combined with vaccination could be cost-effective.[21]

103           To inform decision making within Colombia, we modeled the large-scale implementation of the  
104 *Wolbachia* replacement strategy for controlling dengue in 11 target Colombian cities. Here we  
105 present the resulting cost-effectiveness and benefit-cost analyses.

106

## 107   **Methods**

### 108   Framework

109   The WMP identified 11 target Colombian cities that might be suitable for *Wolbachia* based on  
110 population size, population density, and dengue incidence rates, and provided information about  
111 each city (Supporting Information S1 Table). Altogether, these cities accounted for a third of  
112 Colombia's reported dengue cases from 2010 through 2019. We conducted economic analyses for

113 each of these target cities. Colombia’s capital and largest city, Bogotá, is virtually free of dengue due  
114 to its high altitude, so it was not a target city.

115 The analyses were done by city, as costs, impacts, and funding decisions lie partly at the  
116 municipal level. Our analysis began by estimating the current burden of dengue-related illness in  
117 each of these target cities in terms of average annual numbers of cases, health care costs, and loss of  
118 health from non-fatal dengue cases. We then estimated the expected gains from *Wolbachia* based on  
119 the Yogyakarta cluster randomized trial. Next, we examined the cost of implementing *Wolbachia*  
120 based on the WMP’s recent Colombian projects. Finally, we calculated cost-effectiveness and benefit-  
121 cost ratios showing the ratio of predicted health care gains to estimated costs by city.

## 122 Parameters

123 Table 1 provides the necessary national parameters for the economic analysis with monetary amounts  
124 in 2020 USD.

125

### 126 **Table 1. National Parameters**

Label	Parameter	Value
P1	Average health system cost per dengue case in 2019-20 for cases treated in the medical sector, USD	\$202.11
P2	Average health system cost per dengue case in 2019-20 for cases treated in the medical and non-medical sectors combined, USD	\$116.90

P3	Estimated cost of <i>Wolbachia</i> per km <sup>2</sup> in target cities in Colombia, USD	\$87,625
P4	Estimated % savings in conventional vector control spending, year 1,	0%
P5	Estimated % savings in conventional vector control spending, year 2	20%
P6	Estimated % savings in conventional vector control spending, year 3	30%
P7	Estimated % savings in conventional vector control spending, year 4	40%
P8	Estimated % savings in conventional vector control spending, years 5+	50%
P9	Efficacy of <i>Wolbachia</i> intervention (%), year 1 from date of deployment	37.5%
P10	Efficacy of <i>Wolbachia</i> intervention (%), years 2+ from date of deployment	75.0%
P11	Efficacy of <i>Wolbachia</i> intervention (%), 10-year average	71.3%
P12	Annual discount rate for costs and health effects	3%
P13	DALY/dengue case	0.0476
P13	Share of <i>Wolbachia</i> deployment cost that is incurred in year 1	100%
P15	Share of <i>Wolbachia</i> deployment cost needed for long term monitoring, year 2+	1%
P16	Cumulative present value factor over 10 years using P12	8.53
P17	Colombia GDP/capita (2020), World Bank, market prices, USD	\$5,312
P18	Share of dengue cases correctly reported in surveillance system	29%



P19 Share of *Wolbachia* costs for preparation, before deployment 20.54%

---

127 Legend: DALY=disability-adjusted life year; GDP=gross domestic product; km=kilometers; SOAT=Seguro  
128 Obligatorio para Accidentes de Tránsito (Compulsory Insurance for Traffic Accidents), the reference  
129 prices used by Colombian insurers; USD=United States dollars. Monetary amounts are in 2020 USD at  
130 market exchange rates. Sources: For P1 and P2, items were available only for 2019; these were adjusted  
131 for inflation and changes in exchange rates, giving virtually identical values in 2020 USD as of 2019. For  
132 P3, cost data were provided by the WMP based on its budget projections. They apply to all target cities  
133 except Cali. For Cali, where Phase I implementation had been conducted, delays due to interruptions  
134 from the COVID-19 pandemic increased costs. The COVID interruption raised the projected cost per  
135 km<sup>2</sup> for Cali across all phases to \$96,698.

136 For P12, we relied on a leading textbook on economic evaluation in health.[22] For P13, the disease  
137 burden per case of dengue is the sum of its morbidity and mortality components. The morbidity  
138 component was 0.032.[23] The mortality component was calculated first by dividing the average  
139 number of deaths due to dengue between the years 2012 through 2018 by the average incidence for  
140 these same years. The resulting weighted average case-fatality rate was  $6.05 \times 10^{-4}$ . Based on an  
141 estimated 50 years of remaining life (as young adults are the median age of dengue fatalities) and the  
142 widely recommended discount rate of 3%, the discounted remaining life was calculated using the  
143 following formula: Discounted remaining life =  $[1 - (1 + P12)^{-50}] / P12 = 25.73$ . The mortality component  
144 was 0.0156 DALYs (i.e.  $6.05 \times 10^{-4} \times 25.73$ ). The overall burden per case was 0.0476 DALYs (i.e., 0.032 +  
145 0.0156).

146 P16, the cumulative present value factor, was calculated with the Excel present value function (PV) using  
147 P12 and a time horizon of 10 years, i.e.,  $PV(P12,10,-1)$  equals 8.53; P17 is from the World Bank[24]; all  
148 other items are based on the authors' calculations.

#### 149 Disease burden of dengue

150 The disease burden of dengue in a specified geographical area in a year is best conceptualized as the  
151 product of its number of dengue cases times the disease burden per case. Global research has found  
152 that a substantial share of dengue cases are treated outside the formal health sector, and thus not  
153 captured in existing databases.[25] To apply this concept to Colombia, we assessed the breakdown of  
154 dengue cases by severity and reporting status. We relied on the expertise of three epidemiologists: Luz  
155 Inés Villarreal Salazar (independent consultant in Colombia), Carlos Willian Rincon (University Los  
156 Andes), and Maria Patricia Arbelaez Montoya (World Mosquito Program, Colombia). We adjusted for  
157 underreporting of the number of dengue cases using an adjustment factor derived from *el Sistema*  
158 *Nacional de Vigilancia en Salud Pública (SIVIGILA)* [the National Public Health Surveillance System] and  
159 *Registro Individual de Prestación de Servicios de Salud Municipio de Envigado (RIPS)* [Individual Registry  
160 of Provision of Health Services Municipality of Envigado].

161 To adjust for the fact that routine programs often have fewer resources and less intensive  
162 supervision than research trials, we rounded down the per-protocol efficacy from the Indonesian  
163 cluster randomized trial.[8] We projected that the *Wolbachia* program in Colombia will result in a 75%  
164 reduction in dengue cases once *Wolbachia* is stably established in the mosquito population--the second  
165 year of implementation onwards based on projected time for deployment. Projecting a linear increase  
166 from zero to complete establishment of *Wolbachia* over the first year of implementation, we estimated  
167 a 37.5% reduction in dengue cases overall in the first year.

168 Current cost of a dengue episode

169 The aggregate cost of dengue is the product of the average cost per case times the number of cases. We  
170 used two approaches to estimate the cost of a dengue case in Colombia. Under our main approach, the  
171 average direct cost of a dengue case treated in the formal health system in 2019 was estimated using  
172 the tariffs to pay treatment costs from transit accidents, *Seguro Obligatorio para Accidentes de Tránsito*  
173 (*SOAT*) [Compulsory Insurance for Traffic Accidents]. The *SOAT* tariffs also serve as reference prices in  
174 payment negotiations between insurers and providers. While actual payment rates from other insurers  
175 are not publicly available, experts believe that actual payment rates likely average the *SOAT* rates.  
176 Anecdotal reports suggest that in rural areas, where providers are few, providers are paid above the  
177 *SOAT* rates, whereas in urban areas, where providers are numerous, payers can negotiate discounts  
178 below the *SOAT* rates.

179 We converted the *SOAT* amounts in Colombian pesos to US dollars at the average exchange rate  
180 for the years 2015-2020.[26] For most curative services in the health care system, RIPS provides a  
181 national claims system that captures the health care provided to the insured population by diagnostic  
182 codes, care provided, and care setting. The data include the number of consultations and procedures  
183 used, emergency room visits, and hospitalizations. RIPS categorized dengue cases as classic dengue and  
184 severe dengue. For verification we used the *Suficiencia* [Sufficiency] database, which provides service  
185 payments for calculating the *Unidad de Pago por Capitación (UPC)* [Capitation Payment Unit] and  
186 premium information.[27]

187 Using the *SOAT* tariff, we derived the cost per case through stratification by the severity of  
188 dengue and calculated a weighted average based on the estimated share of dengue cases by severity. To  
189 reflect the fact that a number of non-hemorrhagic (classical) cases were hospitalized, we stratified by

190 severity category instead of treatment setting for consistency among data sources. To report the cost of  
191 all types of dengue cases in Colombia from the health system perspective, we adjusted for cases treated  
192 outside the health care system. To estimate the economic cost, we incorporated both the cost of cases  
193 treated outside the health care system and direct and indirect household expenditures during a dengue  
194 episode. We then analyzed the RIPS claims data to derive the average cost of a non-fatal dengue case  
195 for the years 2015 through 2020 and reported the average 5-year cost per case based on the severity of  
196 dengue, i.e., severe and non-severe dengue. The claims data included the total number and cost of  
197 dengue health care services based on the care setting: consultations, procedures, emergencies, and  
198 hospitalizations.

199 To validate our SOAT-based estimate of the healthcare cost per dengue case, we used aggregate  
200 data (see Supporting Information S2 Text, Supporting Information S3 Table and Supporting Information  
201 S4 Table). [28-33] This aggregate approach, termed macro-costing, used an empirical bed-day  
202 equivalent factor of 0.32 of an ambulatory visit compared to an inpatient day[32] and the average cost  
203 of a hospitalization and an ambulatory visit. Macro-costing remained a secondary estimate, however, as  
204 its applicability rested on the assumption that visits and hospitalizations for dengue consumed the same  
205 resources, on average, as visits and hospitalizations for all causes combined.

#### 206 Disease burden of dengue per case

207 Based on the calculation provided for discounted remaining life, the years of life lost and years lost to  
208 disability per case are 0.0156 and 0.0320,[23] corresponding to shares of 33% and 67%, respectively.  
209 The sum of these two metrics comprised the total disease burden per dengue case of 0.0476 DALYs.

#### 210 Cost of *Wolbachia* deployment

211 To estimate the cost of the *Wolbachia* program in the 11 target cities in Columbia, we started by  
212 analyzing the program budget for Cali. The budget covered two programmatic phases, with each phase  
213 divided into three stages: prepare, release, and short-term monitoring (STM). The budget covered the  
214 administrative and management cost, communication, community engagement, data management,  
215 diagnostic, monitoring, mosquito rearing, the release of the *Wolbachia* mosquitoes, surveillance, site  
216 start-up, project oversight, and indirect (facilities and administrative) costs.

217 The preparation stage lasted 12 and 6 months for phases 1 and 2 of the Cali program,  
218 respectively; release stages each took 6 months, and the STM stage was 12 months. Initially, the WMP  
219 projected that implementation of the *Wolbachia* program would take three years per city. After further  
220 review, however, WMP officials and the authors agreed that expansion of the existing program to  
221 additional cities in Colombia, and likely in other countries in a scale-up phase, could be achieved with  
222 an accelerated timeline and reduced the projected duration.

223 Based on the shortened timeframes, we reduced the durations of projected staff  
224 requirements. We estimated the indirect cost of the *Wolbachia* program at 15% of direct costs. This is  
225 the maximum global rate allowed to grantees by the Bill & Melinda Gates Foundation,[28] a major  
226 sponsor of *Wolbachia* development. Brandeis researchers also reduced the estimated time needed for  
227 preparation, release, and long-term monitoring from 30 months to 15 months. Both adjustments  
228 reduced the overall projected per square kilometer (km<sup>2</sup>) cost of the *Wolbachia* program. To estimate  
229 the overall cost of the program in the 11 target cities, we made the preceding two adjustments to the  
230 budgeted cost of Cali phase 2 deployments to derive an adjusted cost per km<sup>2</sup> (parameter P5). WMP  
231 estimated the projected release area (km<sup>2</sup>) in each target city, including all built-up areas and excluding

232 public spaces, parks, and empty spaces. This area was multiplied by the adjusted cost per km<sup>2</sup>  
233 (parameter P3) to estimate the cost of implementation in the rest of Cali and the 10 other target cities.

234 Our cost projections generated both best estimates and confidence bounds. The uncertainty  
235 reflected alternative estimates of the size of the deployment needed and the cost adjustment  
236 attributable to the pause in Cali phase 1 deployment due to the COVID-19 pandemic. The  
237 implementation costs occur primarily during the first and second years of release and STM, with an  
238 estimated 1% of the initial spending needed annually for long-term monitoring from the second year  
239 onward.

#### 240 Economic appraisal

241 We calculated the medical cost offsets from dengue cases averted each year as the cost per  
242 symptomatic case times the baseline average number of such cases times the fraction averted in each  
243 city year. Although some health economists disagree with discounting future health effects,[34] a  
244 leading textbook and Colombia-specific guidelines recommend that future costs and health benefits  
245 should be discounted.[22, 35] We calculated the present value of the *Wolbachia* program and all cost  
246 offsets in each city over a ten-year time horizon with a discount factor from P12. The vector control  
247 offset was calculated through percentagewise cost savings in parameters P4 through P8. The medical  
248 cost offset comprises the estimated reduction of cases over the ten-year time horizon. The present  
249 value of these offsets was calculated as the annual full-deployment result time the cumulative present  
250 value factor for ten years (parameter P16) less an adjustment for the smaller effectiveness in year 1. If  
251 we had decided not to discount, then the present value costs would have changed little, but the  
252 present value of health impacts would have been substantially higher.

253 To value the indirect benefits (gains in quality and length of life), we needed to assign an  
254 economic value to a year of good health—averting a DALY or gaining a Quality-adjusted Life Year  
255 (QALY). This valuation is equivalent to setting a threshold value for determining the cost-effectiveness  
256 of a health intervention. In 2001, the World Health Organization’s Macroeconomic Commission on  
257 Health recommended thresholds of 1 and 3 times a country’s per capita Gross Domestic Product (GDP)  
258 for an intervention to be “very cost-effective” or “cost effective,” respectively.[36] Subsequently, WHO  
259 officials recommended finding evidence-based thresholds and incorporating fairness and affordability  
260 into the decision process.[37] Economic theory suggests that evidence consider the public’s willingness  
261 to pay (WTP) to avert one DALY or gain one QALY.[22]

262 To apply this concept, we searched PubMed for studies on WTP in Colombia. The one study we  
263 found, modeling chemotherapy for lung cancer, did not present an empirical estimate, but simply  
264 selected a value of US\$17,656, three times Colombia’s then GDP per capita.[38] A wider search, a  
265 systematic global review of WTP studies, found a median value for upper-middle income countries (the  
266 relevant category for Colombia) of US\$5,936, with an interquartile range of US\$7,233.[39] However,  
267 none of the included studies was conducted in Colombia and upper-middle income countries span a  
268 wide range of per capita GDP. However, in 2023, an empirical approach was published for WTP  
269 thresholds and applied to 174 countries.[40] It included Colombia. Based on national data rather than  
270 survey responses, it calculated national WTPs based on the country’s changes in life expectancy and  
271 health expenditures. This approach found that Colombia’s WTP per QALY gained (equivalent to a DALY  
272 averted) was 0.75 times its per capita GDP in 2019. An independent commentary noted the many  
273 advantages of this approach.[41] Like that in most upper-middle income countries, Colombia’s WTP as  
274 a proportion of per capita GDP fell in the range of 0.5 to 1.0. Applying Colombia’s ratio, we valued each

275 DALY in our target year (2020) in Colombia as 0.75 times that year's per capita GDP. That is, each DALY  
276 averted through reduced dengue had an economic value of USD3,984.

277 We calculated each city's benefit-cost ratio as its total economic benefits (including the  
278 economic value of good health) divided by the cost of the deployment. If this ratio exceeded 1.0,  
279 *Wolbachia* was considered a favorable economic investment. The incremental cost-effectiveness ratio  
280 (ICER) is the net present value cost of the *Wolbachia* program divided by its present value health gain in  
281 DALYs. A positive ICER below USD3,984 (0.75 times Colombia's per capita GDP[20] of USD5,312)  
282 indicates that the intervention is cost-effective. A negative ICER indicates that the replacement  
283 strategy is cost saving in that city, i.e., exceptionally cost-effective.

284

## 285 **Results**

### 286 Current cost per case of dengue

287 The epidemiological panel provided the following five categories for the distribution of dengue cases in  
288 Colombia by severity and reporting to SIVIGILA: (1) 2% are severe cases and correctly diagnosed and  
289 reported to SIVIGILA, (2) 27% are non-severe dengue (including those with and without warning signs)  
290 and correctly reported to SIVIGILA, (3) 11% are non-severe dengue, diagnosed by medical providers but  
291 not reported to SIVIGILA due to time and administrative barriers, (4) 20% are non-severe dengue cases  
292 that are misdiagnosed (e.g., diagnosed as a non-specific viral fever), and (5) 40% are mild and do not  
293 interact with the formal healthcare system (i.e. home treatments).

294 Supporting Information S5 Table presents the average cost of a dengue case by severity and  
295 the proportion of dengue cases treated by setting. Only 29% of dengue cases are reported, almost all of



296 which are non-severe dengue. Based on SOAT tariff, we estimated the healthcare cost of care for cases  
297 within the medical system as USD406.37 for a severe case (constituting 6.45% of medical cases) and  
298 USD188.02 for a non-severe medical dengue case (constituting 93.55% of medical cases). The weighted  
299 average healthcare cost per medical case was USD202.11 and USD1.50 for a non-medical dengue case.  
300 The societal cost per case averaged USD151.96, comprised of healthcare costs (averaging USD116.90)  
301 and indirect costs (averaging USD35.06).

### 302 Economic results in target cities

303 Table 2 displays the analytic results of *Wolbachia* releases for each target city and the national total  
304 (sum of all target cities). Table 3 presents the costs and benefits as rates per person covered and gives  
305 final economic results. All benefit cost ratios are favorable or highly favorable, ranging from 1.39 to  
306 8.85.

Table 2. Aggregate costs and DALYs for target cities following the start of *Wolbachia* releases

Rank	Municipality	Adjusted		Initial <i>Wolbachia</i> deployment costs	PV <i>Wolbachia</i> program costs <sup>a</sup>	PV vector control offsets <sup>a</sup>	PV medical cost offsets <sup>a</sup>	PV net costs <sup>a</sup>	PV DALYs <sup>a</sup>
		Adjusted population in release area	release area dengue cases (including unreported)						
1	Cali	2,217,961	27,649	\$8,973,571	\$9,672,263	\$563,261	\$20,086,318	-\$10,977,315	8,174
2	Ibagué	503,745	10,342	\$2,269,484	\$2,446,189	\$238,873	\$7,512,810	-\$5,305,494	3,057
3	Villavicencio	506,145	10,161	\$2,506,072	\$2,701,197	\$309,493	\$7,381,782	-\$4,990,078	3,004
4	Cúcuta	759,395	9,739	\$4,363,719	\$4,703,483	\$1,195,491	\$7,075,123	-\$3,567,131	2,879
5	Bucaramanga	604,186	9,540	\$1,989,085	\$2,143,957	\$803,501	\$6,930,606	-\$5,590,150	2,821
6	Neiva	343,194	7,035	\$1,857,647	\$2,002,286	\$159,430	\$5,110,385	-\$3,267,529	2,080

7	Barranquilla	1,296,471	6,015	\$5,783,242	\$6,233,532	\$226,281	\$4,370,044	\$1,637,207	1,778
8	Valledupar	477,763	3,937	\$2,234,434	\$2,408,410	\$295,246	\$2,860,029	-\$746,866	1,164
9	Armenia	300,785	4,100	\$1,253,036	\$1,350,598	\$124,653	\$2,978,651	-\$1,752,705	1,212
10	Pereira	404,270	3,262	\$1,524,673	\$1,643,386	\$127,747	\$2,369,401	-\$853,762	964
11	Cartagena	926,747	2,460	\$3,864,257	\$4,165,132	\$1,103,887	\$1,786,889	\$1,274,356	727
ALL	National	8,340,662	94,239	\$36,619,221	\$39,470,433	\$5,147,863	\$68,462,037	-\$34,139,468	27,862

---

<sup>a</sup> 10-year present values.

Note: DALYs=disability adjusted life years; PV=present value over 10 years discounted using P12; population in the release areas derived by the World Mosquito Program based on analyses of population density; monetary amounts are in 2020 US dollars. Cities are ranked in decreasing number of average annual dengue cases from 2010 through 2019 (see Supporting Information Table S1).

Table 3. Ratios for target cities following the start of *Wolbachia* releases

Rank	Municipality	PV							Benefit-cost ratio	ICER
		PV <i>Wolbachia</i> deployment costs per person covered	PV conventional vector control offsets per person covered	PV medical care offsets per person covered	PV indirect benefits per person covered	PV overall gross benefits per person covered	PV DALYs averted per 100,000 population			
1	Cali	\$4.36	\$0.25	\$9.06	\$14.68	\$23.99	369	5.50	-\$1,343	
2	Ibagué	\$4.86	\$0.47	\$14.91	\$24.18	\$39.57	607	8.15	-\$1,735	
3	Villavicencio	\$5.34	\$0.61	\$14.58	\$23.65	\$38.84	594	7.28	-\$1,661	
4	Cúcuta	\$6.19	\$1.57	\$9.32	\$15.11	\$26.00	379	4.20	-\$1,239	
5	Bucaramanga	\$3.55	\$1.33	\$11.47	\$18.60	\$31.40	467	8.85	-\$1,982	
6	Neiva	\$5.83	\$0.46	\$14.89	\$24.14	\$39.50	606	6.77	-\$1,571	

7	Barranquilla	\$4.81	\$0.17	\$3.37	\$5.47	\$9.01	137	1.87	\$921
8	Valledupar	\$5.04	\$0.62	\$5.99	\$9.71	\$16.31	244	3.24	-\$642
9	Armenia	\$4.49	\$0.41	\$9.90	\$16.06	\$26.37	403	5.87	-\$1,446
10	Pereira	\$4.07	\$0.32	\$5.86	\$9.50	\$15.68	239	3.86	-\$885
11	Cartagena	\$4.49	\$1.19	\$1.93	\$3.13	\$6.25	78	1.39	\$1,752
ALL	National	\$4.73	\$0.62	\$8.21	\$13.31	\$22.13	334	4.68	-\$1,225

---

Note: DALYs = disability adjusted life years; ICER=incremental cost-effectiveness ratio; PV=present value over 10 years discounted from P12.

Monetary amounts are in 2020 US dollars. Cities are ranked in decreasing number of average annual dengue cases from 2010 through 2019

(see Supporting Information Table S1). National represents the sum of all target cities.

309 To illustrate our results in greater detail, we have focused on Cali. It was the city with  
310 the greatest burden in reported dengue cases. After the Aburrá Valley, where *Wolbachia* had  
311 been deployed previously,[12-15] Cali is the one target city in Colombia in which *Wolbachia* is  
312 already partly deployed. Fig 1 displays the cumulative projected economic benefits of the  
313 *Wolbachia* program in Cali by component and time horizon, where time is the number of  
314 completed years since *Wolbachia* deployment. *Wolbachia* is projected to replace some  
315 conventional vector control, lower the need for medical care for treating dengue illness, and  
316 create economic value of additional healthy years. The overall economic benefits, the sum of  
317 these components, grows with increasing time horizons to USD42.97 per person covered with a  
318 20-year horizon. Over this horizon, indirect benefits (the economic value of reduced illness,  
319 USD26.27) are the largest component, followed by medical care offsets (USD16.20), with vector  
320 control offsets as the smallest benefit (USD0.50),

321

322 <Insert Fig 1 about here>

323

324 The upper (dashed) line in Fig 2 shows the cost per person of implementing the  
325 *Wolbachia* program. The cost per person starts in year 0 with 20.54% of initial program costs  
326 (USD0.83) for planning and engagement of residents and local leaders. The remainder of initial  
327 costs occur in year 1, the year in which city-wide releases would occur, bringing initial program  
328 costs to USD4.05. Thereafter, annual monitoring occurs, if needed, costing 1% of the initial costs  
329 annually throughout the remainder of the time horizon. Thus, cumulative *Wolbachia*  
330 implementation costs per person rise to USD4.20 through 5 years and USD4.63 through 20 years.

331 Whereas longer time horizons generated substantially larger benefits for each of the economic  
332 benefits, they added very little to the present value of *Wolbachia* program costs. The lower  
333 (solid) line is the net healthcare cost at each time horizon. In year 0, when there are no offsets,  
334 it is identical to costs of planning and engagement (USD0.83). In year 1, with some conventional  
335 vector control and medical care offsets, net healthcare costs per person covered reached the  
336 maximum (USD3.50). In subsequent years, healthcare offsets exceed the additional vector  
337 control costs. At 4.3 years, *Wolbachia* becomes cost saving in health care costs. With longer  
338 time horizons, the cost savings continue to grow. Net costs per person become substantial  
339 negative numbers (-USD4.95 and -USD12.08) with the 10- and 20-year horizons, respectively.

340

341 <Insert Fig 2 about here>

342

343 Fig 3 shows the summary outcome measures on health (DALYs averted) and economic  
344 impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a  
345 10-year horizon, the *Wolbachia* program averts 369 DALYs per 100,000 population with a  
346 benefit-cost ratio of 5.50. This highly favorable ratio indicates that every dollar invested  
347 generates USD5.50 in economic benefits for the city's residents through better health and  
348 averting healthcare costs. With a 20-year horizon, these results become almost twice as  
349 favorable, averting 659 DALYs and a benefit-cost ratio of 9.29 to 1. Since the economic benefits  
350 from better health and offsets to health care expenses occur approximately uniformly over time,  
351 the break-even time horizon at which the overall economic benefits exactly offset the costs is  
352 only 1.72 years (21 months) in Cali.

353

354 <Insert Fig 3 about here>

355

356           Extending these results nationally, Fig 4 presents the benefit-cost ratios for all target  
357 cities based on the 10-year horizon. Panel A displays the cities in decreasing order. Projections  
358 for all target cities are favorable, as all the ratios exceed 1.00. Cali is close to the national  
359 average. Cartagena is the most marginal in economic terms (ratio 1.39), while Bucaramanga,  
360 with a ratio of 8.85, is almost twice as favorable as the national average. Panel B shows a scatter  
361 plot of these ratios in relation to population density and average annual dengue incidence.  
362 Higher values of both independent variables tend to be associated with higher (more favorable)  
363 benefit-cost ratios. Dengue incidence is the more important factor as it varies 8-fold from the  
364 least to the most affected city. Higher population density, which varies by a factor of 1.7,  
365 contributes marginally to higher ratios.

366

367 <Insert Fig 4 about here>

368

369

370 **Discussion**



371 Colombia is hyperendemic with dengue.[2] Accounting for cases treated outside the medical  
372 system, misdiagnosed, or otherwise not reported, we concluded that the country's dengue  
373 burden is several times greater than official statistics. Our estimates reinforce previous research  
374 that Colombia's dengue burden exceeds the global average.[17, 25]

375 If implemented with efficacy mirroring the results from the cluster randomized trial,[8]  
376 *Wolbachia* will substantially mitigate dengue incidence in the target cities in Colombia. These  
377 impacts generate highly favorable benefit-cost ratios by helping to avert healthcare and indirect  
378 costs. In over half of the cities, including Cali, the economic benefits exceed USD5.00 for every  
379 dollar invested.

380 *Wolbachia's* costs mostly occur at the beginning, while the health and economic benefits  
381 accrue over time. Therefore, the cost effectiveness and economic benefits of *Wolbachia*  
382 increase with longer time horizons. For example, for each dollar invested, the benefit in Cali  
383 ranged from USD5.50 at 10 years to USD9.29 at 20 years. Thanks to Colombia's national health  
384 insurance system, the medical care component of these benefits would accrue largely to  
385 Colombia's public sector.

386 We used a supplemental method to validate the cost per case of dengue through a  
387 supplemental calculation. The consistency between our main (SOAT) and supplemental (macro-  
388 costing) approaches lent confidence in our results. The difference in cost per case between our  
389 main and supplemental approaches (USD117.50 and USD121.61, respectively) was only 3.5%.  
390 Because the SOAT approach provided greater detail, it was our preferred choice. We explored  
391 performing additional analyses by tier within Colombia's health system, but inconsistencies  
392 precluded doing this reliably with the available data (see Supporting Information S6 Text).

393 Global experience and models raise a caution that *Wolbachia* may not work in isolated  
394 circumstances. As one example, in two nearby sites in Vietnam, *Wolbachia* coverage dropped in  
395 one (Tri Nguyen village) but not in the other (Vinh Luong). Researchers speculated that elevated  
396 temperature in water storage tanks where mosquitoes bred or an interaction with the built  
397 environment may have inhibited *Wolbachia* replication in the ineffective village[42]. As another  
398 example, in small-scale releases in Malaysia, *Wolbachia* were not permanently established  
399 because the selected strain (wAlbB) may have been less fit than the wild mosquitoes.[42]  
400 Modeling studies raise the possibility that dengue viruses could become resistant to *Wolbachia*.  
401 Because of the multiple mechanisms by which *Wolbachia* inhibit dengue transmission, however,  
402 any such resistance, if any, would likely evolve only slowly.[43] Resistance could be identified by  
403 monitoring and possible corrective actions, such as new *Wolbachia* strains.

404 Our very favorable national benefit-cost ratio of 4.68 indicates that our findings are  
405 robust and broadly resistant to such concerns. Our calculations show that the replacement  
406 strategy would remain economically viable nationally even if 10-year efficacy declined by as  
407 much as 78.6%, calculated as  $(4.68 - 1)/4.68$ . With that large a decline costs of USD1.00 would  
408 generate benefits of  $USD4.68 \times (100.0\% - 78.6\%)$  or USD1.00, meaning that the program would  
409 just break even economically.

410 While our benefit-cost ratios compare *Wolbachia* against no dengue control,  
411 policymakers may also wish to consider comparing *Wolbachia* against alternative dengue control  
412 strategies. Among the few trials, an alternative vector control strategy based on community-  
413 based mobilization (*Camino Verde*) proved to be effective but labor intensive and expensive. Its  
414 cost-effectiveness ratios relative to GDP per capita were relatively unfavorable--3.0 in Mexico

415 and 16.9 in Nicaragua.[44] A modeled assessment of screening and vaccination in Colombia with  
416 the first licensed dengue vaccine (Sanofi's Dengvaxia®) gave cost-effectiveness ratios relative to  
417 GDP per capita ranging from 0.47 (in areas with 90% dengue seropositivity among 9 year-olds) to  
418 6.72 (with 10% dengue seropositivity).[45] This strategy proved more cost-effective (lower ICER)  
419 as the percentage of nine-year old seropositive individuals in the population increased.

420 The second dengue vaccine, TAK-003 (Takeda's Qdenga®), was licensed by the  
421 European Medicines Agency in 2022 and received pre-approval by the World Health  
422 Organization in 2024.[46] Published trial results showed TAK-003 reduced dengue fever cases by  
423 80% and, unlike Dengvaxia®, created no added risk for persons with no prior dengue  
424 infection.[46] While preliminary economic models by the manufacturer projected that Qdenga®  
425 would be cost saving in Puerto Rico[47] and Thailand[48], we could not find any related peer-  
426 reviewed economic studies. Fig 4(B) showed that in the 9 of 11 target municipalities with  
427 dengue incidence of at least 500 per 100,000 population, *Wolbachia* also proved cost saving.

428 As resources for public health interventions are limited, it is informative to compare the  
429 cost-effectiveness of *Wolbachia* against that of two other public health preventive interventions  
430 in Colombia. First, a year after Colombia had introduced HPV vaccination into its national  
431 vaccination program,[49] a cost-effectiveness analysis reported its ICER was greater than three  
432 times Colombia's then GDP per capita, so HPV was not then considered cost-effective.[50]  
433 Second, a campaign to encourage COVID-19 vaccination among those at highest risk proved cost-  
434 effective [51] by the latest criteria,[40] but not cost saving.

435 In addition to cost-benefit and cost-effectiveness ratios, policy makers must also  
436 consider the affordability of any proposed program. The first year costs of *Wolbachia*

437 deployment (\$4.05 per person) represent a notable 0.8% of Colombia's 2019 per capita health  
438 expenditure and might appear too expensive if widely implemented at once. However, the  
439 program can become more affordable by phasing deployment across parts of a city over multiple  
440 years (as happened in Cali) or sequencing successive cities in different years.

441 Several limitations should be acknowledged. The number of dengue cases differs  
442 between the RIPS and *Suficiencia* databases, pointing to inconsistencies and/or under-reporting.  
443 Second, differences in numbers of dengue cases treated among different epidemiological  
444 models, macro-costing, RIPS, and SIVIGILA creates uncertainty around the estimated healthcare  
445 cost offsets. Finally, our adjustments for underreporting and misdiagnosis are based on our  
446 panel's expert judgment rather than objective information. However, the extremely favorable  
447 benefit-cost ratios in 9 of our 11 target cities indicate that *Wolbachia* deployment would still be  
448 highly favorable in those cities.

449 Key strengths also deserve highlighting. First, we believe this is the first economic  
450 evaluation of *Wolbachia* in Colombia, building on the empirical record of efficacy and feasibility  
451 from the trial in Indonesia[8] and controlled observational studies in the country.[3, 12-15]  
452 Second, we used an empirical method for valuing indirect benefits based on the overall  
453 economy.[40] As 64% of Colombia's workers were in the informal sector in 2020 and generally  
454 earned less than formal sector workers,[52] this approach is more realistic than applying formal  
455 sector wages to indirect costs of all cases, including those not employed or working informally,  
456 as was done elsewhere.[19] Third, this study's number of sites (11) substantially exceeds the  
457 numbers in previous economic analyses--3 in Indonesia[17] and 7 in Brazil.[19] These multiple  
458 sites provided the insight that not only was *Wolbachia* beneficial overall, but it was especially

459 valuable in cities with high dengue incidence. High population density in the release area was  
460 associated with somewhat more favorable outcomes. As a square kilometer with high dengue  
461 incidence and high population density is one with substantial dengue burden, deploying  
462 *Wolbachia* in such a location will generate substantial economic value. Conversely, areas with  
463 relatively low incidence and low density would benefit much less; another control strategy may  
464 be preferable.[53]

465

## 466 **Conclusions**

467 In conclusion, *Wolbachia* proved economically beneficial in all 11 target cities and cost saving  
468 (paying for itself through treatment costs averted) in the 9 target cities with adjusted incidence  
469 of at least 500 per 100,000 population. In the future, policy makers may have a portfolio of  
470 options to control dengue. Municipalities with both high incidence of dengue and high  
471 population density should strongly consider trying to mobilize the resources for *Wolbachia*  
472 deployment. Areas with high dengue incidence but low population density should consider  
473 vaccination. To address the uncertainties around each dengue control technique, some experts  
474 recommend integrating *Wolbachia*, vaccination, and case management.

475

## 476 **Funding**

477 This work was funded in whole, or in part, by the Wellcome Trust (grant 224459/Z/21/Z) to the  
478 World Mosquito Program (WMP), Monash University (Clayton, VIC, Australia). For the purpose

479 of open access, the author has applied a CC BY public copyright license to any Author Accepted  
480 Manuscript version arising from this submission.

481

## 482 **Author Contributions**

483 **Donald S. Shepard**: conceptualization; formal analysis; funding acquisition; methodology;  
484 supervision; writing—review & editing. **Samantha R. Lee**: data curation; formal analysis;  
485 writing—original draft, review & editing. **Yara A. Halasa-Rappel**: data curation; formal analysis;  
486 writing—original draft, review & editing. **Carlos Rincon Perez**: methodology; data curation;  
487 formal analysis; writing—review & editing. **Arturo Harker Roa**: methodology; data curation;  
488 supervision; writing—review & editing. All authors have read and approved the final version of  
489 the manuscript. Donald S. Shepard had full access to all of the data in this study and takes  
490 complete responsibility for the integrity of the data and the accuracy of the data analysis.

491

## 492 **Acknowledgments**

493 The authors thank Luz Villarreal Salazar for serving on the study’s epidemiologic panel, Ivan  
494 Velez and Patricia Arbelaez Montoya from the WMP Colombia and Reynold Dias and Katherine  
495 Anders from the global WMP (Australia) for Wolbachia cost data and valuable comments, and  
496 Clare L. Hurley of Brandeis University for editorial assistance.

497

## 498 **Conflict of Interest Statement**

499 All authors received funding from the Wellcome Trust under a grant (224459/Z/21/Z) to the  
500 World Mosquito Program (WMP), Monash University (Clayton, VIC, Australia), which had no  
501 role in review nor the decision to submit. The direct sponsor (WMP) had the right to review but  
502 authorized submission with no required changes. Donald S. Shepard has received financial  
503 support from Abbott, Inc, Sanofi, and Takeda Vaccines, Inc. in the past 36 months unrelated to  
504 the present study. All other authors declare no other conflicts of interest.

505

#### 506 **Data Availability Statement**

507 Data access may be requested from the respective Colombian government agencies. For RIPS,  
508 see <https://www.minsalud.gov.co/proteccionsocial/Paginas/rips.aspx>. For population, see  
509 [https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-](https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion)  
510 [poblacion/proyecciones-de-poblacion](https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion).

511

#### 512 **Ethics Statement**

513 This modeling study did not involve any human studies data as it was based entirely on  
514 aggregate or publicly available anonymous data. These data could not allow any individual to  
515 be identified nor linked with any individual. The research team did not prospectively nor  
516 retrospectively recruit human participants nor did the team obtain tissues, data, or samples for  
517 the purposes of this study. The research team did not review existing medical records nor  
518 archived samples. Therefore, this study was outside the purview of the Committee for  
519 Protection of Human Studies in Research so ethical approval was not applicable.

520 **Transparency Statement**

521 The lead author Donald S. Shepard affirms that this manuscript is an honest, accurate, and  
522 transparent account of the study being reported; that no important aspects of the study have  
523 been omitted; and that any discrepancies from the study as planned (and, if relevant,  
524 registered) have been explained.

525

526 **ORCID**

527 Donald S Shepard, (ORCID ID: 0000-0003-2187-0593)

528 Samantha R. Lee, (ORCID ID: 0000-0002-9225-3077)

529 Yara A. Halasa-Rappel, (ORCID ID: 0000-0001-6564-1608)

530 Carlos Rincon Perez, (ORCID ID: 0009-0004-8721-9159)

531 Arturo Harker Roa, (ORCID ID: 0000-0003-2343-1965)



532 **References**

- 533 1. Castro Rodríguez R, Carrasquilla G, Porra A, Galera-Gelvez K, Lopez Yescas JG, Rueda-Gallardo  
534 JA. The burden of dengue and the financial cost to Colombia, 2010–2012. *Am J Trop Med Hyg*  
535 2016;94(5):1065-72. doi: 10.4269/ajtmh.15-0280.
- 536 2. Gutierrez-Barbosa H, Medina-Moreno S, Zapata JC, Chua JV. Dengue infections in Colombia:  
537 Epidemiological trends of a hyperendemic country. *Trop Med Infect Dis.* 2020;5(4):156 doi:  
538 10.3390/tropicalmed5040156.
- 539 3. Humphreys G. Tackling mosquito-borne viruses in the Region of the Americas. *Bull World Health*  
540 *Organ.* 2023;101:441–2. doi: 10.2471/BLT.23.020723
- 541 4. Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, et al. The  
542 wMel Wolbachia strain blocks dengue and invades caged *Aedes aegypti* populations. *Nature.*  
543 2011;476:450–3. doi: 10.1038/nature10355.
- 544 5. Ross PA, Robinson KL, Yang Q, Callahan AG, Schmidt TL, Axford JK, et al. A decade of stability for  
545 wMel Wolbachia in natural *Aedes aegypti* populations. *PLoS Pathog.* 2022;18(2):e1010256. doi:  
546 10.1371/journal.ppat.1010256.
- 547 6. World Mosquito Program. The World Mosquito Program helps protect communities around the  
548 world from mosquito-borne diseases. 2023. Available from:  
549 <https://www.worldmosquitoprogram.org/>.

- 550 7. Soh S, Ho SH, Seah A, Ong J, Dickens BS, Tan KW, et al. Economic impact of dengue in Singapore  
551 from 2010 to 2020 and the cost-effectiveness of Wolbachia interventions. *PLOS Glob Public*  
552 *Health*. 2021;1(10):e0000024. doi: 10.1371/journal.pgph.0000024.
- 553 8. Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, et al. Efficacy of  
554 Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med*.  
555 2021;384(23):2177–86. doi: 10.1056/NEJMoa2030243.
- 556 9. Dufault SM, Tanamas SK, Indriani C, Ahmad RA, Utarini A, Jewell NP, et al. Reanalysis of cluster  
557 randomised trial data to account for exposure misclassification using a per-protocol and  
558 complier-restricted approach. *Scientific Reports*. 2024;14:Article number 11207. doi:  
559 10.1038/s41598-024-60896-9.
- 560 10. Pinto SB, Riback TIS, Sylvestre G, Costa G, Peixoto J, Dias FBS, et al. Effectiveness of Wolbachia-  
561 infected mosquito deployments in reducing the incidence of dengue and other Aedes-borne  
562 diseases in Niterói, Brazil: A quasi-experimental study. *PLoS Negl Trop Dis*. 2021;15(7):0009556.  
563 doi: 10.1371/journal.pntd.0009556.
- 564 11. dos Santos GR, Durovni B, Saraceni V, Souza Riback TI, Pinto SB, Anders KL, et al. Estimating the  
565 effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de  
566 Janeiro, Brazil: a spatiotemporal modelling study. *Lancet Infect Dis*. 2022;22:1587–95. doi:  
567 10.1016/S1473-3099(22)00436-4.
- 568 12. Lenharo M. Dengue rates drop after release of modified mosquitoes in Colombia. *Nature*.  
569 2023;623:235-6. doi: 10.1038/d41586-023-03346-2.

- 570 13. Velez ID, Santacruz E, Kutcher SC, Duque SL, Uribe A, Barajas J, et al. The impact of city-wide  
571 deployment of Wolbachia-carrying mosquitoes on arboviral disease incidence in Medellín and  
572 Bello, Colombia: study protocol for an interrupted time-series analysis and a test-negative  
573 design study (version 2). F1000 Research. 2019. doi: [f1000research.com/articles/8-1327](https://doi.org/10.1093/f1000research/8-1327).
- 574 14. Velez ID, Tanamas SK, Arbelaez MP, Kutcher SC, Duque SL, Uribe A, et al. Reduced dengue  
575 incidence following city-wide wMel Wolbachia mosquito releases throughout three Colombian  
576 cities: Interrupted time series analysis and a prospective case-control study. *PLoS Negl Trop Dis*.  
577 2023;17(11):e0011713. doi: [10.1371/journal.pntd.0011713](https://doi.org/10.1371/journal.pntd.0011713).
- 578 15. Velez ID, Uribe A, Barajas J, Uribe S, Ángel S, Suaza-Vasco JD, et al. Large-scale releases and  
579 establishment of wMel Wolbachia in *Aedes aegypti* mosquitoes throughout the Cities of Bello,  
580 Medellín and Itagüí, Colombia. *PLoS Negl Trop Dis*. 2023;17(11):e0011642. doi:  
581 [10.1371/journal.pntd.0011642](https://doi.org/10.1371/journal.pntd.0011642).
- 582 16. Governorate of Valle del Cauca. This Monday, the 'Wolbachia' project is launched in Yumbo to  
583 combat dengue. 2023. Available from:  
584 [https://www.valledelcauca.gov.co/publicaciones/78449/este-lunes-se-lanza-en-yumbo-el-](https://www.valledelcauca.gov.co/publicaciones/78449/este-lunes-se-lanza-en-yumbo-el-proyecto-wolbachia-con-el-que-se-busca-combatir-el-dengue/)  
585 [proyecto-wolbachia-con-el-que-se-busca-combatir-el-dengue/](https://www.valledelcauca.gov.co/publicaciones/78449/este-lunes-se-lanza-en-yumbo-el-proyecto-wolbachia-con-el-que-se-busca-combatir-el-dengue/).
- 586 17. Brady OJ, Kharisma DD, Wilastonegoro NN, O'Reilly KM, Hendrickx E, Bastos LS, et al. The cost-  
587 effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: A  
588 modelling study. *BMC Med*. 2020;18(1):186. doi: [10.1186/s12916-020-01638-2](https://doi.org/10.1186/s12916-020-01638-2).

- 589 18. Turner HC, Quyen DL, Dias R, Huong PT, Simmons CP, Anders K. An economic evaluation of  
590 Wolbachia deployments for dengue control in Vietnam. *PLoS Negl Trop Dis*.  
591 2023;17(5):e0011356. doi: 10.1371/journal.pntd.0011356.
- 592 19. Zimmermann IR, Fernandes RRA, da Costa MGS, Pinto M, Peixoto HM. Simulation-based  
593 economic evaluation of the Wolbachia method in Brazil: A cost-effective strategy for dengue  
594 control. *Lancet Reg Health Am*. 2024;35:100783. doi: 10.1016/j.lana.2024.100783.
- 595 20. Shepard DS, Hariharan D, Ratu A, Anders K. Cost-benefit analysis of Wolbachia to control dengue  
596 in Suva, Fiji and Port Vila, Vanuatu. Annual Conference of the American Society of Tropical  
597 Medicine and Hygiene (virtual meeting, presentation 1449, Slide 14. 15-19 Nov 2020).
- 598 21. Knerer G, Currie CSM, Brailsford SC. The economic impact and cost-effectiveness of combined  
599 vector-control and dengue vaccination strategies in Thailand: Results from a dynamic  
600 transmission model. *PLoS Negl Trop Dis*. 2020;14:e0008805. doi: 10.1371/journal.pntd.0008805.
- 601 22. Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. *Methods for Economic*  
602 *Evaluation of Health Care Programmes*. Fourth Edition. New York Oxford; 2015.
- 603 23. Zeng W, Halasa-Rappel YA, Durand L, Coudeville L, Shepard DS. Impact of a nonfatal dengue  
604 episode on disability-adjusted life years: A systematic analysis. *Am J Trop Med Hyg*.  
605 2018;99(6):1458-65. doi: 10.4269/ajtmh.18-0309.
- 606 24. The World Bank. GDP per capita (current US\$). 2020. Available from:  
607 <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CO,%20Accessed%207/29/20>  
608 22.

- 609 25. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: A  
610 systematic analysis. *Lancet Inf Dis*. 2016;16(8):935-41. doi: 10.1016/S1473- 3099(16)00146-8.
- 611 26. Exchange Rates. US dollar to Colombian peso spot exchange rates for 2016. 2023. Available  
612 from: <https://www.exchangerates.org.uk/USD-COP-spot-exchange-rates-history-2016.html>.
- 613 27. Gobierno de Colombia M. Condiciones de salud para ajuste de riesgo de la UPC y mecanismo de  
614 incentivos para el mejoramiento de la calidad y los resultados en salud [Health conditions for  
615 UPC risk adjustment and incentive mechanism for quality improvement and health outcomes].  
616 2022. Available from:  
617 [https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/condiciones-salud-](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/condiciones-salud-upc-incentivos-calidad-resultados-salud-2022.pdf)  
618 [upc- incentivos-calidad-resultados-salud-2022.pdf](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/condiciones-salud-upc-incentivos-calidad-resultados-salud-2022.pdf).
- 619 28. Bill and Melinda Gates Foundation. Indirect Cost Guidelines. 2010. Available from:  
620 [https://docs.gatesfoundation.org/documents/historical\\_indirect\\_cost\\_policy.pdf](https://docs.gatesfoundation.org/documents/historical_indirect_cost_policy.pdf).
- 621 29. Gobierno de Colombia M. Estructura del gasto en Salud Pública en Colombia, Papeles en Salud.  
622 Edición No 17. 2018. Available from:  
623 [https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PES/estructura-gasto-](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PES/estructura-gasto-salud-publica-colombia.pdf)  
624 [salud- publica-colombia.pdf](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PES/estructura-gasto-salud-publica-colombia.pdf).
- 625 30. Ministerio de Salud y Protección Social. Cifras de aseguramiento en salud. 2022. Available from:  
626 <https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx>.
- 627 31. Organization for Economic Cooperation and Development (OECD). Health at a Glance 2021:  
628 OECD Indicators. Paris: OECD Publishing; 2021. Available from:  
629 <https://doi.org/10.1787/ae3016b9-en>.

- 630 32. Shepard DS, Hodgkin D, Anthony YE. Analysis of Hospital Costs: A Manual for Managers. Geneva,  
631 Switzerland: World Health Organization; 2000.
- 632 33. Worldometer. Colombia population. 2022. Available from:  
633 <https://www.worldometers.info/world-population/colombia-population/>.
- 634 34. Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the economic evaluation of health  
635 care interventions for priority setting in the health system: an update from WHO CHOICE. Int J  
636 Health Policy Manag. 2021;10(11):673–7. doi:10.34172/ijhpm.2020.244.
- 637 35. Faria R, Duarte A, McKenna C, Revill P, Cary M, Byford S. Guidelines for the economic evaluation  
638 of healthcare technologies in Colombia: technical support documents. Bogota: Instituto de  
639 Evaluación Tecnológica en Salud; 2014. Available from:  
640 [https://www.iets.org.co/Archivos/66/Documentos\\_tecnicos\\_en\\_ingles.pdf](https://www.iets.org.co/Archivos/66/Documentos_tecnicos_en_ingles.pdf).
- 641 36. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and  
642 health: Investing in health for economic development: Executive summary. 2001. Available  
643 from: <http://www.who.int/iris/handle/10665/42463>.
- 644 37. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kienya M-P, et al. Cost–  
645 effectiveness thresholds: Pros and cons. Bull World Health Organ. 2016;94:925–30. doi:  
646 10.2471/BLT.15.164418.
- 647 38. Lasalvia P, Hernández F, Gil-Rojas Y, Rosselli D. Incremental cost-effectiveness analysis of  
648 tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the  
649 epidermal growth factor receptor in Colombia. Expert Review of Pharmacoeconomics &  
650 Outcomes Research. 2021;21(4):821-7. doi: 10.1080/14737167.2020.1779063

- 651 39. Nu Vu A, Hoang MV, Lindholm L, Sahlen KG, Nguyen CTT, Sun S. A systematic review on the  
652 direct approach to elicit the demand side cost-effectiveness threshold: Implications for low- and  
653 middle-income countries. *PLoS One*. 2024;19(2):e0297450. doi: 10.1371/journal.
- 654 40. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the  
655 efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries  
656 based on growth in life expectancy and health expenditures. *Lancet Glob Health*.  
657 2023;11(6):e833-e42. doi: 10.1016/S2214-109X(23)00162-6.
- 658 41. Cao Z, Chen S. Innovative methods of determining health expenditure efficiency are urgently  
659 needed. *Lancet Glob Health*. 2023;11(6):e797-e8. doi: 10.1016/S2214-109X(23)00196-1.
- 660 42. Hien NT, Anh DD, Le NH, Yen NT, Phong TV, Nam VS, et al. Environmental factors influence the  
661 local establishment of *Wolbachia* in *Aedes aegypti* mosquitoes in two small communities in  
662 central Vietnam. *Gates Open Res*. 2022;5:147. doi: 10.12688/gatesopenres.13347.2.
- 663 43. Edenborough KM, Flores HA, Simmons CP, Fraser JE. Using *Wolbachia* to eliminate dengue: Will  
664 the virus fight back? *J Virol*. 2021;95:e02203-20. doi: 10.1128/JVI.02203-20.
- 665 44. Tschampl CA, Undurraga EA, Ledogar RJ, Coloma J, Legorreta-Soberanis J, Paredes-Solis S, et al.  
666 Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in  
667 Nicaragua and Mexico: A cluster randomized controlled trial. *Int J Infect Dis*. 2020;94:59–67. doi:  
668 10.1016/j.ijid.2020.03.026.
- 669 45. Coudeville L, Baurin N, Shepard DS. The potential impact of dengue vaccination with, and  
670 without, pre-vaccination screening. *Vaccine*. 2020;38(6):1363–9. doi:  
671 10.1016/j.vaccine.2019.12.012.

- 672 46. World Health Organization. WHO prequalifies new dengue vaccine. Geneva: WHO; 2024.  
673 Available from: <https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue->  
674 vaccine.
- 675 47. Kaul RR. Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico.  
676 2023. Available from: [https://stacks.cdc.gov/view/cdc/130011/cdc\\_130011\\_DS1.pdf](https://stacks.cdc.gov/view/cdc/130011/cdc_130011_DS1.pdf)
- 677 48. Shen J, Kharitonova E, Biswal S, Sharma M, Aballea S, TytuEa A, et al. Disease impact and cost-  
678 effectiveness of a new dengue vaccine TAK003 in Thailand. *International Journal of Infectious*  
679 *Diseases*. 2023;130(Supplement 2):S141. doi: 10.1016/j.ijid.2023.04.347.
- 680 49. Pan American Health Organization (PAHO). Colombia Introduces HPV Vaccine into National  
681 Immunization Schedule. 2012. Available from:  
682 [https://www3.paho.org/hq/index.php?option=com\\_content&view=article&id=7358:2012](https://www3.paho.org/hq/index.php?option=com_content&view=article&id=7358:2012).
- 683 50. Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW. Cost-  
684 effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a  
685 societal perspective in Colombia. *PloS One*. 2013;8(11):e80639. doi:  
686 10.1371/journal.pone.0080639.
- 687 51. Morales-Zamora G, Espinosa O, Puertas E, Fernández JC, Hernández J, Zakzuk V, et al. Cost-  
688 effectiveness analysis of strategies of COVID-19 vaccination in Colombia: Comparison of high-  
689 risk prioritization and no prioritization strategies with the absence of a vaccination plan. *Value*  
690 *Health Reg Issues*. 2022;31:101-10. doi: 10.1016/j.vhri.2022.04.004.
- 691 52. Danish Trade Union Development Agency, Norwegian Confederation of Trade Unions. Labour  
692 Market Profile Colombia – 2023/2024. Copenhagen: Ulandssekretariatet; 2023. Available from:



693 <https://www.ulandssekretariatet.dk/wp-content/uploads/2023/06/LMP-Colombia-2023->  
694 [final.pdf](#).

695 53. Ooi EE, Wilder-Smith A. Externalities modulate the effectiveness of the Wolbachia release  
696 programme. *Lancet Inf Dis.* 2022;22(11):1518-9. doi: 10.1016/S1473-3099(22)00497-2.

697

698 **Figure Legends**

699 Fig 1. Economic benefits of *Wolbachia* by component and time horizon

700

701 Fig 2. Gross and net healthcare costs of *Wolbachia* by component and time horizon

702

703 Fig 3. Program impacts (DALYs and benefit-cost ratios) in Cali by time horizon

704 Note: DALYs denote disability adjusted life years

705

706 Fig 4. Estimated benefit-cost ratios by city with a 10-year horizon

707

708

709 **Supporting Information**

710 S1 Table. Input data for target cities

711 S2 Text: Macro-costing approach

712 S3 Table. Macro-costing approach to estimate the average cost of an outpatient visit and hospitalization

713 (monetary amounts in 2020 USD)

714 S4 Table. Health care cost of dengue cases by type of dengue diagnosis and setting using macro-costing

715 (amounts in 2019-2020 USD)

716 S5 Table. Cost of dengue case by dengue type (Tarifa SOAT for reported), 2019-20 USD

717 S6 Text.




Figure 2




Figure 1




Figure 3





Figure 4